The head of the first clinical study with the Corona vaccine the company Curevac to the University hospital of Tübingen is expecting in two months, with the first results.
“This will go pretty fix,” said Professor Peter Kremsner, Director of the Institute for tropical medicine where the active ingredient is tested.
The subjects of the investigations were underway on Thursday, but the first vaccination had not yet been made.
Tolerability and immune response will be examined
The first subject was a young man. “He will then be monitored for first 24 hours with us in the Department,” said Kremsner. The goal of the first Phase of the study was to learn about the compatibility and the immune system.
After more than 100 healthy Volunteers between the ages of 18 and 60 years of age to participate in the study.
The tübingen-based company Curevac is working on so-called mRNA-vaccines. mRNA is a type of messenger molecule, in which the Instructions for the production of proteins is.
For your vaccine Curevac have provided researchers mRNA with the Instruction for a Protein of the Coronavirus Sars-CoV-2. The human cells after vaccination of this Protein, which the body recognizes as foreign. He, however, makes antibodies and other immune cells.
For the University hospital of Tübingen, it was a home game, said Kremsner. In Phase two of the study, the group of subjects is to be extended to older people. Also, children should get the vaccine candidates at some point.
Two months in the preparation of the study took approximately 30 employees were involved.
Deutsche Presse-Agentur (dpa)
*The article “Coronavirus: results of the first vaccine trial is expected in the summer,” published by FitForFun. Contact with the executives here.